Financial reports
10-K
2023 FY
Annual report
22 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
10-Q
2023 Q1
Quarterly report
22 May 23
NT 10-Q
Notice of late quarterly filing
15 May 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
13 May 22
10-K
2021 FY
Annual report
15 Apr 22
Current reports
8-K
Results of Operations and Financial Condition
22 Mar 24
8-K
Regulation FD Disclosure
11 Mar 24
8-K
Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering
8 Feb 24
8-K
Developing innovative therapeutics to address unmet needs Corporate Presentation / January 2024 www.revbiosciences.com
30 Jan 24
8-K
Material Modifications to Rights of Security Holders
23 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
22 Jan 24
8-K
Results of Operations and Financial Condition
13 Nov 23
8-K
Developing innovative therapeutics to address unmet needs Corporate Presentation / October 2023 www.revbiosciences.com
12 Oct 23
8-K
Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors
2 Oct 23
8-K
Results of Operations and Financial Condition
11 Aug 23
Registration and prospectus
424B3
Prospectus supplement
2 Feb 24
S-1/A
IPO registration (amended)
30 Jan 24
S-1/A
IPO registration (amended)
29 Jan 24
S-1
IPO registration
22 Dec 23
S-8
Registration of securities for employees
11 Aug 23
424B3
Prospectus supplement
10 Feb 23
S-1MEF
Registration of additional securities for an S-1
9 Feb 23
S-1/A
IPO registration (amended)
9 Feb 23
S-1/A
IPO registration (amended)
1 Feb 23
25-NSE
Exchange delisting
13 Jan 23
Proxies
DEF 14A
Definitive proxy
15 Apr 24
PRE 14A
Preliminary proxy
5 Apr 24
DEF 14A
Definitive proxy
22 Dec 23
PRE 14A
Preliminary proxy
12 Dec 23
DEFA14A
Additional proxy soliciting materials
7 Jul 23
DEFA14A
Additional proxy soliciting materials
15 Jun 23
DEF 14A
Definitive proxy
5 May 23
PRE 14A
Preliminary proxy
25 Apr 23
DEFA14A
Additional proxy soliciting materials
13 Jan 23
DEF 14A
Definitive proxy
30 Dec 22
Other
EFFECT
Notice of effectiveness
1 Feb 24
CORRESP
Correspondence with SEC
30 Jan 24
CORRESP
Correspondence with SEC
29 Jan 24
UPLOAD
Letter from SEC
2 Jan 24
EFFECT
Notice of effectiveness
10 Feb 23
CORRESP
Correspondence with SEC
6 Feb 23
CORRESP
Correspondence with SEC
1 Feb 23
EFFECT
Notice of effectiveness
21 Nov 22
CORRESP
Correspondence with SEC
17 Nov 22
CORRESP
Correspondence with SEC
16 Nov 22
Ownership
SC 13G/A
Lind Global Fund II LP
13 Feb 24
SC 13G
SABBY MANAGEMENT, LLC
3 Jan 24
4
GEORGE F TIDMARSH
12 Dec 23
4
GEORGE F TIDMARSH
18 Oct 23
4
GEORGE F TIDMARSH
17 Oct 23
3
Lakhmir S Chawla
2 Oct 23
4
GEORGE F TIDMARSH
2 Oct 23
144
Notice of proposed sale of securities
28 Sep 23
4
GEORGE F TIDMARSH
18 Sep 23
4
GEORGE F TIDMARSH
19 Apr 23